Diagnostic and Prognostic Values of Admission Procalcitonin Levels in Community-Acquired Pneumonia in an Intensive Care Unit

N. Boussekey, O. Leroy, H. Georges, P. Devos, T. d’Escrivan, B. Guery

Abstract
Background: Measurement of procalcitonin (PCT) has been studied for several years in infectious diseases. Some studies have focused on community-acquired pneumonia (CAP) but only one was conducted in critically ill patients hospitalized in an intensive care unit (ICU).

Patients and Methods: To determine the diagnostic and prognostic role of PCT in patients admitted in an intensive care unit for severe CAP, 110 patients hospitalized in our unit were prospectively studied. Within 48 hours following ICU admission, PCT serum level was measured with a quantitative method above a threshold value of 0.5 ng/ml.

Results: Initially focusing on the diagnostic value of PCT, 20% of the patients had a serum PCT level < 0.5 ng/ml, 30% between 0.5 ng/ml and 2 ng/ml, and 50% ≥ 2 ng/ml. Serum PCT level was higher in microbiologically documented CAP (median = 4.9 ng/ml vs 1.5 ng/ml if no bacteria were found; p = 0.001), but was not predictive of any specific bacterial agent. Concerning the prognostic value, the serum PCT level was higher for bacteremic patients and/or septic shock patients (4.9 ng/ml vs 1.5 ng/ml; p = 0.0003). Moreover, PCT levels were increased in patients who developed, during their ICU stay, infection-related complications (septic shock, multiorgan dysfunction, acute respiratory distress syndrome and disseminated intravascular coagulation). Finally, the initial PCT level was significantly higher in patients who died during the ICU stay (5.6 ng/ml vs 1.5 ng/ml; p < 0.0001). Such a relationship was not found with C-reactive protein (CRP).

Conclusion: In ICU patients admitted for severe CAP, initial PCT values could be an interesting predictor for complications and mortality.

Introduction
Numerous studies have been designed to identify sensitive and specific markers to differentiate inflammatory from infectious diseases and more specifically to separate bacterial from viral or fungal infections. According to several authors, procalcitonin (PCT) could be an interesting candidate. In healthy individuals, the serum PCT concentration is lower than 0.1 ng/ml but any infectious or inflammatory injury, inducing tumor necrosis factor and/or interleukin-6 release, increases the PCT serum level. Elevation of this peptide in inflammatory disorders has been known since 1975 [1], and the understanding of its pathophysiology has improved during the last three decades [2, 3]. In 1993, Assicot et al. [4] confirmed a potential PCT level relevance in the diagnosis and prognosis of infectious diseases. Animals as well as clinical studies have confirmed that procalcitonin is a potentially useful marker in the diagnosis of infectious diseases. Moreover, its level usually correlates with systemic involvement and prognosis [5–7]. However, only a few studies have focused on community-acquired pneumonia (CAP) [8–13], and among them, only one was performed in intensive care unit (ICU) patients [14]. We therefore decided to study the diagnostic and prognostic values of PCT, measured upon admission to the ICU, for patients admitted for severe CAP.

Patients and Methods
Study Location and Patient Selection
The study was conducted in the Intensive Care and Infectious Disease Unit of Tourcoing Hospital from January 1, 2001 to April 1, 2003. All consecutive patients exhibiting a severe CAP, for which the PCT level was determined within 48 h of ICU admission, were prospectively included in an observational cohort study.

CAP was defined by the following criteria observed at initial presentation or within 48 h following hospitalization: admission from home, presence of a new radiographic pulmonary infiltrate, acute onset of at least one “major” (cough, sputum production,
fever) or two “minor” (dyspnea, pleuritic chest pain, altered mental status, pulmonary consolidation on physical examination, total leukocyte count > 12,000/mm³) clinical or biological findings suggestive of pneumonia. Patients hospitalized within 30 days prior to developing pneumonia, with radiographic abnormalities attributed solely to pulmonary embolus, lung carcinoma or congestive heart failure were excluded [15, 16].

The criteria for ICU admission were those defined by the American Thoracic Society by using a rule that required the presence of either two of three minor criteria (systolic blood pressure < 90 mmHg, multilobar disease, pao₂/FiO₂ ratio < 250) or one of two major criteria (need for mechanical ventilation or septic shock) [17].

**Data Collection and Definitions**

For all patients, the following characteristics were prospectively collected upon ICU admission: age, gender, indication(s) of ICU admission, underlying clinical conditions, severity of illness, and vital sign abnormalities. The underlying clinical conditions were classified, according to the criteria proposed by McCabe and Jackson [18], as nonfatal, ultimately fatal or rapidly fatal. Immunosuppression was defined as a leukocyte count < 1,000/mm³, recent use of systemic corticosteroids (> 10 mg/day of prednisone or equivalent for over 2 weeks), underlying malignancy, cytotoxic drugs, radiation treatment, or asplenia. Severity of illness was assessed by SAPS II [19] and organ system failure (OSF) scoring defined by Knaus [20] to which we added criteria for hepatic failure [21]. Neurological and mental status was stratified according to the Glasgow coma score [22]. Shock was defined as a sustained (> 1 h) decrease in the systolic blood pressure of at least 40 mmHg from baseline or a resultant systolic blood pressure < 90 mmHg after adequate fluid replacement and in the absence of any anti-hypertensive drug [23].

Within 48 h following ICU admission, we prospectively collected, at the same time, the following variables: temperature, leukocyte and platelet counts, C-reactive protein (CRP), and PCT values. PCT level was measured with a quantitative method allowing the comparison of mean or median. PCT values were then used to stratify the patients into three different classes according to the cutoffs recommended by the manufacturer: PCT < 0.5 ng/ml (probable exclusion of any bacterial infection), ≥ 2 ng/ml (probable diagnosis of bacterial infection) and ≥ 0.5 and < 2 ng/ml (no definitive conclusion).

Continuous variables were expressed as mean, standard deviation, median and quartiles. Categorical parameters were expressed as frequencies. Comparisons between groups were performed using the χ² test or Fisher’s exact test for categorical parameters. Continuous variables were analyzed using t-test, analysis of variance, Kruskall-Wallis or Wilcoxon’s tests, according to the normality of the parameter, the number of groups compared and the sample size of the groups. Differences between groups were considered to be significant for variables yielding a p-value ≤ 0.05. ROC curves were computed for PCT and CRP in order to assess the sensitivity and specificity to predict either a positive bacterial etiology or death. All analyses were performed using the SAS Software, V8.2 [27].

**Results**

**Patients**

A total of 110 patients with severe CAP were included. The mean age was 58.8 ± 16.3 years, and 64% were male. On ICU admission, SAPS II, Glasgow coma score and OSF score values were 43 ± 21.2, 12.5 ± 4, and 1.6 ± 1, respectively. According to the McCabe classification, ultimately and rapidly fatal underlying diseases were present in 57 and seven patients, respectively. The main organ dysfunctions on ICU admission are reported in Table 1. Among the 92 patients admitted with respiratory distress, 74 required mechanical ventilation: 65 were intubated and nine were treated with noninvasive ventilation. 42 patients (38.2%) developed septic shock: 16 were treated with dopamine, 14 with dobutamine, 12 with noradrenaline, and seven with adrenaline. For seven patients continuous hemofiltration was performed.

**Diagnostic Value of PCT**

The mean level of procalcitonin was 24 ± 80 ng/ml. The median value was 2 ng/ml, with a lower quartile at 0.6 ng/ml and an upper quartile at 8.6 ng/ml. Of the patients, 50% had a PCT level > 2 ng/ml, 30% had a level between 0.5 and 2 ng/ml, and 20% had a level < 0.5 ng/ml.

A causative organism was identified in 48 patients (43.7%). Predominant pathogens were S. pneumoniae (43.8%), gram-negative bacilli (37.5%), and Staphylococcus aureus (18.7%). In gram-negative bacilli, Haemophilus influenzae and Escherichia coli were frequently isolated. Median initial PCT level was higher when an etiologic
agent was recovered (4.9 ng/ml [1.2–20.8] vs 1.5 ng/ml [0.4–4.9]; p = 0.0009). Median values of PCT according to the causative pathogen were as follow: *S. pneumoniae*: 6.5 ng/ml (3.5–37), gram-negative bacteria: 1.4 ng/ml (0.6–7.1), and *S. aureus*: 4.3 ng/ml (1.1–61). A PCT level ≥ 2 ng/ml was found in 81% of patients with pneumococcal CAP, in 43.8% of patients with CAP due to gram-negative bacilli, and in 72.7% of patients with CAP due to another agent (essentially *S. aureus*). In patients without any microbial documentation, a PCT level ≥ 2 ng/ml was observed in 37.1% of cases (Table 2).

The ROC analysis did not allow the identification of a specific threshold to differentiate positive from negative documented CAP based on PCT as well as CRP values: the areas under the curve were 0.597 for the CRP, and 0.685 for the PCT, respectively (Figure 1).

In the three groups of patients classified based on the PCT level, we determined the mean values of clinical and biological parameters collected on the day of PCT measure (Table 3). No significant relationship was found between PCT levels and body temperature or leukocyte count. In contrast, mean CRP values significantly increased with PCT levels (p = 0.04). However, the mean CRP value was already high (138 ± 140 mg/l) in the group of patients who had a PCT level < 0.5 ng/ml. Finally, the PCT level was inversely associated with platelet count (p = 0.001).

**Prognostic Value of PCT**

Ten patients exhibited bacteremia associated with CAP. Causative organisms were *S. pneumoniae* (n = 7), *E. coli* (n = 2), and *S. aureus* (n = 1). Procalcitonin level was > 2 ng/ml in nine patients exhibiting bacteremic CAP. In the remaining patient, the PCT level was 1.8 ng/ml. No patient with bacteremia had a PCT level < 0.5 ng/ml.

The PCT level significantly increased in the presence of septic shock (5.1 ng/ml [2.4–41] vs 1.4 ng/ml [0.6–5.4];

---

Table 1

| Organ dysfunctions on admission. | No. | %  |
|----------------------------------|-----|----|
| Respiratory dysfunction          | 92  | 83.6|
| Hemodynamic dysfunction          | 37  | 33.6|
| Renal dysfunction                | 21  | 19.1|
| Hematologic dysfunction          | 6   | 5.5 |
| Hepatic dysfunction              | 4   | 3.6 |
| Neurologic dysfunction           | 14  | 12.7|
| Immunosuppression                | 14  | 12.7|

Respiratory dysfunction: respiratory rate ≤ 5/min or ≥ 49/min, PaCO2 ≥ 50 mmHg, AaDO2 ≥ 350 mmHg or mechanical ventilation. Hemodynamic dysfunction: heart rate ≤ 56/min, mean blood pressure ≤ 49 mmHg, ventricular tachycardia or fibrillation or pH ≤ 7.24 with PaCO2 ≤ 49 mmHg. Renal dysfunction: urine output ≤ 479 ml/24h, serum urea ≥ 100 mg/100 ml or serum creatinine ≥ 3.5 mg/100 mL. Hematologic dysfunction: leucopenia ≤ 1,000/mm³, thrombocytopenia ≤ 20,000/mm³ or hematocrit ≤ 20%. Hepatic dysfunction: serum bilirubin > 30 mg/l without hemolysis, ALAT > 2 × normal or hepatic encephalopathy. Neurologic dysfunction: Glasgow coma score < 6 without sedation.

---

Table 2

| Causative pathogen | PCT < 0.5 ng/ml | 0.5 ≤ PCT < 2 ng/ml | PCT ≥ 2 ng/ml | P-value* |
|--------------------|-----------------|---------------------|--------------|----------|
| None               |                 |                     |              |          |
| Positive           |                 |                     |              |          |
| - *Streptococcus pneumonia* | 18 (29) | 21 (33.9) | 23 (37.1) | 0.003    |
| - Gram-negative bacilli | 6 (8.3) | 12 (25) | 32 (66.7) |          |
| - Other            | 0               | 3 (27.3)            | 8 (72.7)     |          |

* data are presented as no. (%); P = comparison between all the groups.

---

**Figure 1.** ROC curve: PCT, CRP and bacterial documentation.
p = 0.0002) and increased with the number of organ dysfunction (no dysfunction: 1.4 ng/ml [0.4–2.1]; n = 21, 1 or 2 dysfunctions: 1.7 ng/ml [0.6–7.6]; n = 70, and more than 2 dysfunctions: 12.3 ng/ml [2.5–125] n = 19; p = 0.0001). The PCT level was more often ≥ 2 ng/ml in patients exhibiting > 1 organ dysfunction (p = 0.0006) (Table 4).

A total of 41% of patients developed complications during their ICU stay: 17.3% a superinfection, 34.6% infection-related complications (ARDS: 22.7%, septic shock: 30%, MOF: 18.2%, DIC: 10.9%). In patients developing infection-related complications, initial PCT levels were significantly higher (5.4 ng/ml [1.8–18] vs. 1.3 ng/ml [0.4–5.7]; p < 0.001).

Of the patients who developed an infection-related complication during their ICU stay, 73% had a PCT value ≥ 2 ng/ml on admission, whereas only 5.3% of them had a value < 0.5 ng/ml (p = 0.0007). The relationship between an initial PCT level > 2 ng/ml and the ultimate occurrence of infection-related complications was found for any kind of complication (Table 5).

30 (27.3%) of the 110 patients died during their ICU stay. The median value of PCT for the survivors was 1.5 ng/ml (0.6–5.4) compared to 5.6 ng/ml (2.4–61) for the deceased (p < 0.0001). Mortality rate significantly increased according to the initial PCT level (Table 6). In patients exhibiting an initial PCT level > 2 ng/ml, mortality rate was 41.8% (23/55). This percentage dropped to 12.7% when PCT level was below 2 ng/ml (p = 0.0006).

In the survivors and deceased, mean values of CRP were 150 mg/l and 210 mg/l, respectively. We tried to find CRP and PCT cutoff values that were significantly related to mortality with a ROC curve (Figure 2). Sensitivity and specificity of these measures were insufficient to estimate survival (area under the curve: 0.57 for CRP, 0.723 for PCT).

### Table 4

**Prognostic value of PCT according to organ dysfunctions and septic shock**

| No. | PCT < 0.5 ng/ml | 0.5 ≤ PCT < 2 ng/ml | PCT ≥ 2 ng/ml | P-value |
|-----|----------------|---------------------|--------------|---------|
|     | 22             | 33                  | 55           |         |
| Bacteremia | 0              | 1                   | 9            | 0.03    |
| Septic shock | 1 (2.4)       | 11 (26.2)           | 30 (71.4)    | 0.0002  |
| Organ dysfunction | 0 or 1       | 19 (31.1)          | 20 (32.8)    | 0.0006  |
|              | > 1            | 3 (6.1)             | 13 (26.5)    |         |

*a data are presented as no. (%); b comparison between all the groups

### Table 5

**Prognostic value of PCT and complications**

| No. | PCT < 0.5 ng/ml | 0.5 ≤ PCT < 2 ng/ml | PCT ≥ 2 ng/ml | P-value |
|-----|----------------|---------------------|--------------|---------|
|     | 22             | 33                  | 55           |         |
| Sepsis-related complications | 2 (5.3)         | 8 (21)              | 28 (73.7)    | 0.0007  |
| – ARDS | 2 (8)         | 3 (12)              | 20 (80)      | 0.003   |
| – Septic shock | 2 (6.1)      | 7 (21.2)            | 24 (72.7)    | 0.005   |
| – MOF | 2 (10)         | 1 (5)               | 17 (85)      | 0.002   |
| – DIC | 0 (0)          | 1 (8.3)             | 11 (91.7)    | 0.009   |

*a data are presented as no. (%); b comparison between all the groups
Discussion

Even if the admission mean PCT value is far above the critical cutoff threshold of 2 ng/ml (24 ± 80 ng/ml), 50% of the patients had values < 2 ng/ml, and 20% < 0.5 ng/ml. These results suggest that this marker is not an interesting tool to diagnose severe CAP. However, to assess CAP severity PCT appears to be a better indicator: a high level is associated with a high incidence of bacteremia, severe sepsis, infection-related complications, and finally, mortality.

During the last decade, the measurement of procalcitonin became a common tool in infectious diseases management, particularly in sepsis with bacteremia [29, 30, 38]. However, sensitivity and specificity of this parameter remain low in localized [5] or moderate infections [31, 32]. Studies evaluating PCT in CAP are sparse and, most of the time, with a limited number of patients. Studies focusing on patients with moderately severe CAP without sepsis demonstrated that the increase in PCT was not constant (60% of the patients) [8, 9], and moderate (usually < 0.5 ng/ml) [10, 11]. Only one study was performed in patients exhibiting severe CAP requiring ICU admission: the median PCT value was > 2 ng/ml [14]. Our data are consistent with this result; however, we must underline that, even if the mean PCT level on ICU admission was far over the cutoff value set at 2 ng/ml, only 50% of our patients had an initial PCT level ≥ 2 ng/ml. Moreover, for 20% of the patients, the PCT value < 0.5 ng/ml. Consequently, PCT does not appear as a significant marker for the positive diagnosis of CAP since a level < 0.5 ng/ml could not rule out the diagnosis and could delay the initiation of an empiric antibiotic treatment.

The role of PCT measurement to predict a causative organism incriminated in sepsis remains unclear. Most of the studies demonstrated that PCT levels appeared quite similar in sepsis due to gram-positive or gram-negative bacteria [28, 29]. In lower respiratory tract infections, PCT level is low when causative organisms are atypical pathogens or Mycobacterium spp. [8–10]. In the present study, PCT levels appeared significantly higher when a causative organism was identified (4.9 ng/ml vs 1.5 ng/ml; p = 0.0009). Although we found no precise relationship between a PCT level and a group of causative agents, we noticed that most patients with pneumococcal CAP (81%) had an initial PCT level > 2 ng/ml. This could be explained by the high frequency of bacteremia associated with pneumococcal CAP in our series (7/21 patients). In patients without identification of a causal organism, we found a high percentage (63%) of PCT levels < 2 ng/ml. A virus or intracellular bacteria could be involved. CAP diagnosis may also have been overestimated, even if the patient fulfilled all inclusion criteria.

When comparing PCT to other usual markers of infection, we noted a significant relationship between CRP and PCT. Consistent with other authors, CRP values were always higher than baseline, even in patients with a PCT value < 0.5 ng/ml [8, 31]. In fact, if PCT is a better marker of sepsis than CRP [28, 35], CRP appears to be more useful in localized infections. In respiratory tract infections, CRP levels are usually high, even in patients exhibiting a moderately severe CAP [12]. Nevertheless, CRP is not the best marker based on its kinetic properties, and its inflammation-related production. Consequently, we think these two measures must be interpreted carefully in the diagnosis of CAP.

In our series, ten patients (9%) were bacteremic; nine had an initial PCT level ≥ 2 ng/ml and none a level < 0.5 ng/ml. Several studies showed, in bacteremia, that the

Table 6
Prognostic value of PCT and mortality.

| No.        | PCT < 0.5 ng/ml | 0.5 ≤ PCT < 2 ng/ml | PCT ≥ 2 ng/ml | P-valueb |
|------------|----------------|---------------------|---------------|----------|
| Deceased   | 22             | 3 (10)              | 4 (13.3)      | 23 (76.7) | 0.003    |
| Survivors  | 19 (23.7)      | 49 (36.3)           | 32 (40)       | 0.003    |

a data are presented as no. (%); b comparison between all the groups

Figure 2. ROC curve: PCT, CRP and mortality.
initial PCT level was usually high [32, 33]. Some authors even proposed the use of specific cutoff values for bacteremia: a level < 0.5 ng/ml would suggest the absence of bacteremia and > 20 ng/ml would be in favor of a bacteremic episode [28, 34]. In our study, we never observed a PCT level < 0.5 ng/ml in bacteremia, supporting the exclusion of bacteremia in this case. On the contrary, a PCT level > 2 ng/ml did not appear to be such a good predictor of bacteremia since 46 of the 55 patients exhibited a high level without positive blood cultures. In spite of these results, we realize that the prognostic value for bacteremia is difficult to evaluate with only ten patients.

We found that the serum PCT level increased significantly with the severity of the sepsis, particularly when more than one organ failed, and when an infection-related complication such as ARDS, DIC, or septic shock occurred. This relationship between the PCT level and the severity of illness (systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock) has been previously reported [14, 30, 35, 36]. The PCT level increases with the number of organ failures [31, 37]. When compared to the other inflammatory markers (CRP, interleukin-6, interleukin-8, D-dimers, tumor necrosis factor), PCT always appears as the best indicator to assess the severity of sepsis [30, 31, 38]. Our results are in agreement with these data suggesting that PCT measurement is more interesting to estimate the severity of a CAP than to confirm a diagnosis.

Although we were unable to find a PCT level to predict mortality, a significant and positive relationship between the initial PCT level and the mortality rate was observed. In experimental studies, animals receiving PCT had, compared with controls, a higher mortality rate, whereby an injection of an antiserum directed against procalcitonin improved survival [38, 39]. In clinical studies, a correlation between mortality rate and PCT level on admission was reported in most publications including patients with severe sepsis or septic shock [28, 40]. Some authors even proposed to include the PCT level in scores assessing sepsis severity on ICU admission [41]. In a few studies, although a correlation between PCT level on admission and survival did not appear, an increase in PCT levels within the first 48 h following admission appeared as a risk factor of death, whereas a decrease was associated with a better outcome [30, 42]. In CAP, the initial PCT level was not so clearly related to prognosis. Brunkhorst et al. [14] studied 93 patients with severe CAP and ventilator-associated pneumonia in an ICU, the median initial PCT level was 2.3 ng/ml. PCT levels were measured daily during the first 5 days of hospitalization and never correlated with prognosis. However, the authors underlined that an increase in PCT levels at the end of the observation period was a poor prognostic factor. In a second study reporting 96 patients with moderately severe CAP, PCT was not correlated to mortality, but the median PCT level was 0.2 ng/ml and only two patients died [9].

Our study has several limitations: first, recent studies showed that the PCT level decreases rapidly after hospital admission for CAP [9, 14]. The blood samples were collected within the first 48 h after admission because of limited laboratory availability in our hospital; therefore, our results must be taken with caution. For the same reason, we did not perform repeated samples to evaluate PCT kinetics. Second, our method can only measure a PCT level > 0.5 ng/ml. It was recently shown in CAP that values from 0.1 to 0.5 ng/ml could help diagnose a bacterial origin and guide antibiotic treatment [15]. Some of our patients may have developed pulmonary diseases without any bacterial agent, even if they had criteria defined as severe CAP.

In conclusion, measurement of PCT appears as an interesting marker in the management of CAP, even if no particular level appears sensitive enough to be useful for the diagnosis. Consequently, it must always be used in association with the other usual infectious markers. The prognostic value of PCT seems to be more interesting: a PCT level > 2 ng/ml upon ICU admission is associated with an increased rate for the evolution of septic shock, multiorgan dysfunctions, and mortality. However, alone its value seems insufficient to classify the patients.

References

1. Canale DD, Donabedian RK: Hypercalcitoninemia in acute pancreatitis. J Clin Endocrinol Metab 1975; 40: 738–741.
2. Robertson GM Jr, Moore EW, Switz DM, Szemore GW, Estep HL: Inadequate parathyroid response in acute pancreatitis. N Engl J Med 1976; 294: 512–516.
3. Becker KL, Silva OL, Snider RH et al.: The pathophysiology of pulmonary calcitonin. In: Becker KL, Gazdar AF (eds): The endocrine lung in health and disease. WB Saunders Co., Philadelphia PA 1984, pp 277–279.
4. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohouc C: High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993; 341: 515–518.
5. Venet C, Tardy B, Zény F: Biologic markers of infection in intensive care unit in adults: place of the procalcitonin. Réanimation 2002; 11: 156–171.
6. Simon L, Gauvin F, Anne DK, Saint-Louis P, Lacroix J: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206–217.
7. Becker KL, Nylen ES, White JC, Muller B, Snider RH: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors (review). J Clin Endocrinol Metab 2004; 89: 1512–1525.
8. de Werra I, Jaccard C, Corradin SB, Chiolero R, Yersin B, Gallati H, Assicot M, Bohouc C, Baumgartner JD, Glauser MP, Heumann D: Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997; 25: 607–613.
9. Hedlund J, Hansson LO: Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000; 28: 68–73.
Infection 33 · 2005 · No. 4 © Urban & Vogel

10. Zarka V, Valat C, Lemarie E, Boissinot E, Carre P, Besnard JC, Diet P: Serum procalcitonin and respiratory tract infections. Rev Pneumol Clin 1999; 55: 365–369.

11. Nylen ES, Snider RH, Thompson KA, Rohatgi P, Becker KL: Pneumonitis-associated hyperprocalcitonemia. Am J Med Sci 1996; 312: 12–18.

12. Polzin A, Pletz M, Erbes R, Raffenberg M, Mauch H, Wagner S, Arnold G, Lode H: Procalcitonin as a diagnostic tool in lower tract infections and tuberculosis. Eur Respir J 2003; 21: 939–943.

13. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600–607.

14. Brunkhorst FM, Al-Nawas B, Krummenauer F, Forczyk ZF, Shah PM: Procalcitonin, C-reactive protein and Apache II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002; 8: 93–100.

15. Leroy O, Santre C, Beuscart C, Georges H, Guery B, Jacquier JR, Beauche A: A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Int Care Med 1995; 21: 24–31.

16. Fine MJ, Orlloff JR, Arisumi D, Fang GD, Arena VC, Hanusa BH, Yu VL, Singer DE, Kapoor WN: Prognosis of patients hospitalized with community-acquired pneumonia. Am J Med 1990; 88 (5N): 1N–8N.

17. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GE, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL; American Thoracic Society: Guidelines for the management of patients with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163: 1730–1754.

18. McCabe WR, Jackson CG: Gram-negative bacteremia: etiology and ecology. Arch Intern Med 1962; 110: 847–855.

19. Le Gall JR, Lemeshow S, Saulnier F: Simplified acute physiologic score. A new simplified acute physiologic score (SAPSII) based on European/North American multicenter study. JAMA 1993; 27: 2957–2963.

20. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: Prognosis in acute organ system failure. Ann Surg 1985; 202: 685–693.

21. Tran DD, Groenevald AB, Van Der Meulen J, Nauta JJ, Strack van Lethwijk L, Gorus LK: Plasma procalcitonin and C-reactive protein in acute circulatory failure in critically ill patients. Int Care Med 2000; 26 (Suppl.1): S153–S158.

22. Teasdale G, Jennet B: Assessment of coma and impaired consciousness: a clinical scale. Lancet 1974; 81: 84–84.

23. Bone RC, Fischer CJ, Clemmer TR, Slotman GI, Metz CA, Balk RA: The methylprednisolone severe sepsis study group. Sepsis syndrome: a valid clinical entity. Crit Care Med 1989; 17: 389–393.

24. Antibiotic Committee of the French Society for Microbiology: Official Statement. Pathol Biol 1999; 47: 845–872.

25. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy L, Le Gall JR, Morris A, Spragg R: The American-European consensus conference on ARDS. Am J Respir Crit Care Med 1994; 149: 818–824.

26. Bollaert PE, Annane D, Aube H: Intravascular disseminated coagulation in intensive care unit: definition, classification and treatment. Conference of consensus ANAES, October 1, 2001.

27. SAS Institute Inc. SAS/STAT guide for personal computers, version 8.2 ed. Cary, North Carolina: SAS Institute, 2001.

28. Cheval C, Timsit JF, Garrouste-Orgeas M, Assicot M, De Jonghe B, Misset B, Bohouc J, Carlet J: Procalcitonin is useful in predicting the bacterial origin of an acute circulatory failure in critically ill patients. Int Care Med 2000; 26 (Suppl.1): S153–S158.

29. Muller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, Ritz R: Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28: 977–983.

30. Harbarth S, Holecikova K, Foidaveaux C, Pittet D, Ricou B, Grau GE, Vadai L, Pugin J: Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164: 396–402.

31. Suprin E, Canu M, Gallou M, Le Tulzo Y, Lavoue S, Feuillu A, Thomas R: Procalcitonin: a valuable indicator of infection in a medical ICU. Int Care Med 2000; 26: 1232–1238.

32. Ugarte H, Silva E, Mercan D, De Mendoca A, Vincent JL: Procalcitonin used as a marker of infection in the intensive care unit. Crit Care Med 1999; 27: 498–504.

33. Bossink AW, Groeneveld AB, Thijss LN: Prediction of microbial infection and mortality in medical patients with fever: plasma procalcitonin, neutrophil elastase-alpha-antitrypsin, and lactoferrin compared with clinical variables. Clin Infect Dis 1999; 29: 398–407.

34. Chirouze C, Schuhmacher H, Rabaud C, Gil H, Kahynt N, Estavoyer JM, May T, Hoen B: Low serum procalcitonin level accurately predicts the absence of bacteremia in adults patients with acute fever. Clin Infect Dis 2002; 35: 156–161.

35. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlino A: Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med 2003; 31: 1737–1741.

36. Balci C, Sungurtekin H, Gurses E, Sungurtekin U, Kaptanoglu B: Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit. Crit Care Med 2003; 31: 83–90.

37. Giamarellos-Bourboulis EJ, Megam A, Reppa P, Scarp A, Koratzinis G, Thomopoulos G, Giamarello H: Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patients? Int Care Med 2002; 28: 1351–1356.

38. Nylen ES, Whang KT, Snider RH, Steinwald PM, White JC, Becker KJ: Mortality is increased by procalcitonin and decreased by an antisera reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26: 1001–1006.

39. Wagner KE, Martinez JM, Vath SD, Snider RH, Nylen ES, Becker K, Muller B, White JC: Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med 2002; 30: 2233–2237.

40. Pettita V, Hynminen M, Tikkanen O, Kuusela P, Valtone M: Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Int Care Med 2002; 28: 1220–1225.

41. Viallon A, Zény F, Laporte-Simitsidis S, Lambert C, Lafond P, Tardy PM: Serum procalcitonin and respiratory tract infections. Rev Med Interne 2004; 36: 600–607.

42. Claeys R, Vinken S, Spapen H, Ver Helst K, Decochez K, Huyghens L, Gorus LK: Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med 2002; 30: 757–762.